GEAN.ST Genetic Analysis AS

Healthcare Diagnostics & Research Stockholm Exchange
0.6660 NOK
Close of Oct 14, 2026
0.4200 0.9000
Market cap
NOK 46.0M
P/E
-
P/B
1.70x
ROE
-68.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GEAN.ST undervalued?

Graham number

The Graham number of Genetic Analysis AS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genetic Analysis AS fundamental analysis

No fundamental analysis for Genetic Analysis AS yet.

Genetic Analysis AS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genetic Analysis AS

Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome resear…

Full company profile